Vyhledat

New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use

Ochrana osobních údajů - farmakovigilance - Animal Health

Mastitis dairy cows prevent antibiotic resistance

The Clinical and Laboratory Standards Institute (CLSI) approved revised interpretive criteria for the susceptibility testing of a mastitis product.

FRONTLINE® becomes Brand of the Year 2021-22

FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards

GioTag Final Data

Final analysis of GioTag study data showed sequential afatinib followed by osimertinib is a feasible therapeutic strategy in EGFR M+ NSCLC patients

InPedILD_trial_enrollment

First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents

new_analysis_nintedanib_SSc_ILD

Interim analysis results support long term treatment with nintedanib in SSc-ILD patients

Perceived burden of COPD is higher for younger patients

New global survey reveals perceived burden of disease is greater in younger people living with COPD

FDA- HFpEF-breakthrough-designation-EMPEROR-preserved

U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction

reduced-heart-failure-treatment-approval-europe

European approval for treatment of adults with heart failure with reduced ejection fraction

O nás

Lidské zdraví

Zdraví zvířat

Věda a inovace

Partnerská spolupráce

Vyhledat

Nádory trávicí trubice a zažívacích orgánů

Chráníme zvířata i lidi

Deprese

COVID-19

Koně

Zanechme stopu – Sázíme stromy

Onemocnění plic

Pacienti na prvním místě

Fibrilace síní

Naše odpovědnost

Proč bereme péči o onkologické pacienty osobně

Kardiovaskulární onemocnění

Onemocnění sítnice

Větší Potenciál

VPOIS

Uncommon_Mutations_Database